Anogenital Warts Clinical Trial
Official title:
An Open-label, Single-center Triqal to Evaluate Systemic Exposure of Catechins From Commercially Available, Topically Applied Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers
Investigation of systemic catechin exposure following topically administered Veregen® 15%
ointment in patients with external genital and perianal warts and following oral intake of a
standardized green tea beverage in healthy subjects.
Pharmacokinetic parameters for the main catechin EGCg used as a marker of overall catechin
exposure following dermal administration in the patient group will only be calculated if
sufficiently consistent data can be obtained e.g. sufficient plasma catechin concentrations
to pharmacokinetically evaluate plasma profiles for plasma catechin concentrations.
If applicable, a safety margin for ointment use might need to be established with respect to
intolerable systemic exposures of catechins following application of Veregen® ointment.
In treatment arm 1, patients with anogenital warts will apply Veregen® 15% ointment 250 mg
three times daily: in the morning, at midday, and in the evening on the defined anogenital
administration area (total dose of 750 mg/d) for one week .
In treatment arm 2, healthy subjects will ingest 500 mL commercially available green tea
beverage ("Lipton® Green Limone" distributed by PepsiCo Deutschland GmbH, Neu-Isenburg,
Germany), three times daily in the morning, at midday, and in the evening (total dose of
1500 mL/d) for one week.
Plasma samples will be collected to aim for a complete pharmacokinetic assessment (over 24
hours) on Days 1 and 2 at Visit 2 and on Days 7 and 8 at Visit 3 (one week after first
dosing).
To avoid any influence on overall systemic catechin exposure deriving from any other source
than Veregen® or Lipton Green Tea, all subjects participating in the trial (patients and
healthy volunteers) will be asked to follow a defined diet abstaining from food or beverages
known to containing catechins (a list of all prohibited and allowed foods and beverages will
be provided to all subjects).
For concomitant medication, only paracetamol and oral contraceptives are allowed.
n/a
Allocation: Non-Randomized, Endpoint Classification: Bio-availability Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02015260 -
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
|
Phase 2 | |
Completed |
NCT05156541 -
Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts
|
Phase 3 | |
Completed |
NCT01532102 -
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
|
Phase 1/Phase 2 | |
Completed |
NCT02276521 -
Evaluation of Long Term Immunity Following HPV Vaccination
|
Phase 2/Phase 3 | |
Completed |
NCT02377999 -
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
|
Phase 2 | |
Completed |
NCT01387412 -
The Role of Genital Warts in HIV Acquisition in Peru
|
N/A |